[A22-64] Nirmatrelvir/ritonavir (COVID-19) – Benefit assessment acc. to § 35a Social Code Book V
Last updated 04.10.2022
Project no.:
A22-64
Commission:
Commission awarded on 29.06.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults with COVID-19 who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19
Hint of major added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.